Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial
Phytomedicine · 2024-07 · 130 · 155398
DOI: 10.1016/j.phymed.2024.155398 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Phytomedicine, 2024-07. Verfasst von Qiaohong Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Institute of L…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Drugs, Chinese Herbal, Alanine Transaminase, Gastrointestinal Microbiome. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Shenkang Hospital Development Center.
Abstract (Originalsprache)
BACKGROUND: The effective treatment of non-alcoholic fatty liver disease (NAFLD) is an unmet medical need. Qushi Huayu (QSHY) is an empirical herbal formula with promising effects in NAFLD rodent models and a connection to gut microbiota regulation. HYPOTHESIS/PURPOSE: This study aimed to evaluate the effects of QSHY in patients with NAFLD through a multicenter, randomized, double-blind, double-dummy clinical trial. STUDY DESIGN: A total of 246 eligible patients with NAFLD and liver dysfunction were evenly divided to receive either QSHY and Dangfei Liganning capsule (DFLG) simulant or QSHY simulant and DFLG (an approved proprietary Chinese medicine for NAFLD in China) for 24 weeks. The primary outcomes were changes in liver fat content, assessed using vibration-controlled transient elastography, and serum alanine aminotransferase (ALT) levels from baseline to Week 24. RESULTS: Both QSHY and DFLG led to reductions in liver fat content and liver enzyme levels post-intervention (p < 0.05). Compared to DFLG, QSHY treatment improved ALT (β, -0.128 [95 % CI, -0.25, -0.005], p = 0.041), aspartate transaminase (β, -0.134 [95 % CI, -0.256 to -0.012], p = 0.032), and fibrosis-4 score (β, -0.129 [95 % CI, -0.254 to -0.003], p = 0.044) levels. QSHY markedly improved gut dysbiosis compared to DFLG, with changes in Escherichia-Shigella and Bacteroides abundance linked to its therapeutic effect on reducing ALT. Patients with a high ALT response after QSHY treatment showed superior reductions in peripheral levels of phenylalanine and tyrosine, along with an elevation in the related microbial metabolite p-Hydroxyphenylacetic acid. CONCLUSION: Our results demonstrate favorable clinical potential for QSHY in the treatment of NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Institute of Liver Diseases, Shuguang Hospital affiliated to Shanghai University of…
- Department of gastroenterology, Baoshan District Hospital of Integrated Traditional Chinese Medicine of Shanghai, Shanghai 201900, China.
- Department of Infectious disease, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
- Department of gastroenterology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
- School of Pharmacy, Shanghai University of Traditional ChineseMedicine, Shanghai 201203, China.
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Shenkang Hospital Development Center
Zitieren
APA
Liu, Q., Li, X., Pan, Y., Liu, Q., Li, Y., He, C., Zheng, N., Wang, Y., Wang, H., Wang, Y., Sheng, L., Zhang, B., Shen, T., Wu, G., Li, H., Wang, X., Zhang, W., Hu, Y., & Zhao, Y. (2024). Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial. Phytomedicine, 130, 155398. https://doi.org/10.1016/j.phymed.2024.155398
Vancouver
Liu Q, Li X, Pan Y, Liu Q, Li Y, He C, et al. Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial. Phytomedicine. 2024;130:155398. doi:10.1016/j.phymed.2024.155398
BibTeX
@article{Liu2024,
author = {Liu, Qiaohong and Li, Xiaojing and Pan, Yuqing and Liu, Qian and Li, Ying and He, Cong and Zheng, Ningning and Wang, Yan and Wang, Huichao and Wang, Yan and Sheng, Lili and Zhang, Binbin and Shen, Tianbai and Wu, Gaosong and Li, Houkai and Wang, Xiaosu and Zhang, Wei and Hu, Yiyang and Zhao, Yu},
title = {Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial},
journal = {Phytomedicine},
year = {2024},
volume = {130},
pages = {155398},
doi = {10.1016/j.phymed.2024.155398}
}
EUVIMED